MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Danish operator BlueNord remains on track to achieve plateau production at its Tyra II hub by February, after earlier ...